Sg3 Management, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $241,106 - $423,371	-2,900 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $319,232 - $414,467	2,900 New	2,900 $344,000
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $2.37 Million - $3.33 Million	-24,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$65.78 - $105.02 $1.12 Million - $1.79 Million	17,000 Added 242.86%	24,000 $2.33 Million
Q1 2021 May 17, 2021	BUY	$64.07 - $91.75 $192,209 - $275,250	3,000 Added 75.0%	7,000 $478,000
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $2.53 Million - $3.82 Million	-38,925 Reduced 90.68%	4,000 $343,000
Q3 2020 Nov 13, 2020	BUY	$59.04 - $77.95 $2.53 Million - $3.35 Million	42,925 New	42,925 $2.79 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.